MedTrace Logo

New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.

NCT05992337 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-08-16

No results posted yet for this study

Summary

Early detection and thus rapid therapy of cardiotoxicity related to chemotherapy are essential for restoring cardiovascular function. The complete recovery of the cardiovascular system decreases with time to identify the presence of cardiotoxic damage. The project aims to define new biomarkers for the early detection of cardiotoxicity in patients treated with chemotherapy.

Conditions

  • Cardiotoxicity
  • Chemotherapy Effect
  • Chemotherapy Induced Systolic Dysfunction

Interventions

DIAGNOSTIC_TEST

Blood sampling

Blood sample collection for mRNA determination

DIAGNOSTIC_TEST

Echocardiography

Echocardiography for detection of ventricular dysfunction

DIAGNOSTIC_TEST

Cardio MRI

MRI for early detection of myocardial impairment caused by chemotherapy

DIAGNOSTIC_TEST

24-hours monitoring of ECG

Diagnostic test for detection of arrhythmias as a consequence of cardiotoxicity

DIAGNOSTIC_TEST

24 hours monitoring of BP

Diagnostic test for detection of hypertension as a consequence of cardiotoxicity

Sponsors & Collaborators

  • BioVendor LM

    collaborator UNKNOWN

  • Oncology Center Medicon

    collaborator UNKNOWN

  • Cardiology Prague

    lead NETWORK

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2024-11-30
Completion
2025-01-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05992337 on ClinicalTrials.gov